BlossomHill reports Q2 2026 results, FDA Fast Track for lung cancer drug BH-30643Sep 18Quarterly updateBH-30643BlossomHill Therapeutics
BlossomHill reports 45% response rate for BH-30643 in EGFR C797S lung cancerSep 15Clinical readoutBH-30643BlossomHill Therapeutics
BlossomHill Therapeutics prices IPO at $16.00 per share, raising $150 millionAug 7FinancingBlossomHill Therapeutics
BlossomHill Therapeutics files S-1 for IPO on Nasdaq under "BLSM"Jul 16FinancingBlossomHill Therapeutics
Sign inSign in